secwatch.observer — SEC 8-K summary
======================================

Issuer:     Avalo Therapeutics, Inc. (AVTX)
CIK:        0001534120
Form:       8-K
Filed at:   2025-06-18T23:59:59+00:00
Accession:  0001628280-25-032011
Event type: leadership
Sentiment:  positive
Materiality: 0.45
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Avalo Therapeutics appoints former ChemoCentryx CMO Rita Jain to board
----------------------------------------------------------------------

- Dr. Rita Jain appointed to Avalo's Board of Directors effective June 17, 2025.
- She previously served as EVP and CMO at ChemoCentryx, advancing Tavneos for ANCA vasculitis.
- Received initial non-qualified stock option for 40,200 shares, vesting over three years.
- Board also adopted Amended Non-Employee Director Compensation Plan to attract qualified directors.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1534120/000162828025032011/0001628280-25-032011-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1534120/000162828025032011/avtx-20250617.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-032011

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer